Health Trials

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

ConditionOral Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-90
SponsorProteocyte Diagnostics Inc.

About this trial

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Eligibility criteria

Qualifiers

Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma

Disqualifiers

Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy

Trial design

Treatments tested in this trial

  • Standard of Care Histopathology
  • STRATICYTE Assessment

Treatment groups

500 Participants
are divided into 1 treatment group

Locations

3
Kingsway Oral & Maxillofacial SurgeryT5M 3Z7, EdmontonAlberta, Canada
University of AlbertaT6G 1C9, EdmontonAlberta, Canada
Western UniversityN6A 5C1, LondonOntario, Canada

Sponsors and collaborators

Proteocyte Diagnostics Inc.

Lead sponsor

Source ClinicalTrials.gov